<p>温哥華，不列顛哥倫比亞省 --（Newsfile Corp. -2025 年 12 月 17 日）- InMed Pharmaceuticals Inc.（納斯達克：INM）（&#34; <strong>InMed</strong>&#34;或&#34; <strong>公司</strong>&#34;），是一家專注於開發針對高未滿足醫療需求疾病的專有小分子藥物候選者的製藥公司，今天確認，在 2025 年 12 月 17 日舉行的年度股東大會和特別股東會議（&#34; <strong>會議</strong>&#34;）上，股東們對 InMed 在 2025 年 11 月 3 日發佈的會議通知和管理信息通函中提出的事項進行了投票。會議上，共有 993,491 股公司的普通股，約佔公司已發行和流通的 2,804,186 股普通股的 35.43%，以親自或委託代理的方式出席。</p>
<p>會議上董事會（&#34; <strong>董事會</strong>&#34;）選舉的投票結果如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>董事</strong></td>
<td><strong>贊成票</strong></td>
<td><strong>棄權票</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>數量</strong></td>
<td><strong>百分比</strong></td>
<td><strong>數量</strong></td>
<td><strong>百分比</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Eric A. Adams</strong></td>
<td>125,352</td>
<td>82.03%</td>
<td>27,469</td>
<td>17.98%</td>
</tr>
<tr>
<td><strong>Andrew Hull</strong></td>
<td>125,315</td>
<td>82.00%</td>
<td>27,506</td>
<td>18.00%</td>
</tr>
<tr>
<td><strong>Nicole Lemerond</strong></td>
<td>125,485</td>
<td>82.11%</td>
<td>27,336</td>
<td>17.89%</td>
</tr>
<tr>
<td><strong>Neil Klompas</strong></td>
<td>125,444</td>
<td>82.09%</td>
<td>27,377</td>
<td>17.91%</td>
</tr>
<tr>
<td><strong>John Bathery</strong></td>
<td>125,227</td>
<td>81.94%</td>
<td>27,594</td>
<td>18.06%</td>
</tr>
</tbody>
</table>
<p>此外，股東們投票批准 CBIZ CPAs P.C.作為公司下一年的審計師。</p>
<p>股東們還投票批准根據與 YA II PN, Ltd.於 2025 年 6 月 13 日修訂的備用股權購買協議，潛在發行 20% 或更多截至 2024 年 12 月 13 日公司已發行和流通的普通股，符合納斯達克上市規則 5635(d) 和 5635(b)（&#34; <strong>SEPA</strong>&#34;）。</p>
<p>InMed 於 2025 年 12 月 17 日在 SEDAR+ 上提交了投票結果報告，網址為 www.sedarplus.ca。</p>
<p><strong>關於 InMed：</strong></p>
<p>InMed Pharmaceuticals 是一家專注於開發針對 CB1/CB2 受體的專有小分子藥物候選者的製藥公司。InMed 的產品線包括針對阿爾茨海默病、眼科和皮膚科適應症的三個獨立項目。有關更多信息，請訪問 www.inmedpharma.com。</p>
<p><strong>關於前瞻性信息的警示説明：</strong></p>
<p>本新聞稿及公司及其高管和董事的口頭聲明包含適用證券法意義上的&#34;前瞻性信息&#34;和&#34;前瞻性聲明&#34;（統稱為&#34;前瞻性信息&#34;）。前瞻性聲明通常通過&#34;預計&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;潛在&#34;、&#34;可能&#34;、&#34;將&#34;及類似表達來識別。這些聲明基於管理層當前的預期，固有地涉及許多已知和未知的風險、不確定性和假設，其中許多超出我們的控制。前瞻性信息基於管理層當前的期望和信念，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與前瞻性聲明中描述的結果有實質性差異。在不限制前述內容的情況下，前瞻性信息包括但不限於關於 H.R. 5371，即&#34;2026 年持續撥款、農業、立法部門、軍事建設和退伍軍人事務及擴展法案&#34;（&#34; <strong>法案</strong>&#34;）的聲明，法案對 BayMedica Inc.的影響，法案的任何潛在修改及/或其時機，以及 BayMedica 和公司的可選方案，關於開發針對高未滿足醫療需求疾病的專有小分子藥物候選者的聲明，以及關於根據 SEPA 潛在發行普通股的聲明。</p>
<p>此外，存在已知和未知的風險因素，可能導致 InMed 的實際結果、表現或成就與前瞻性信息中表達或暗示的任何未來結果、表現或成就有實質性差異。InMed 的年度報告（10-K 表格）及其季度報告（10-Q 表格）、當前報告（8-K 表格）以及向證券交易委員會提交或提供的任何其他文件中披露了 InMed 業務面臨的風險和不確定性。</p>
<p>本文件中的所有前瞻性信息均受到本警示聲明的完全限制，InMed 不承擔修訂或更新任何此類前瞻性信息的義務，也不承擔公開宣佈任何修訂結果以反映未來結果、事件或發展的義務，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg"/></p>
<p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/278446</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/278446/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/278446/375"/></p>

<p>InMed Pharmaceuticals Inc. 宣佈了其 2025 年年度股東大會和特別會議的結果。股東們對多個事項進行了投票，包括董事會的選舉和批准 CBIZ CPAs P.C. 作為審計師。他們還批准了根據備用股權購買協議可能發行 20% 或更多公司普通股的提案。約 35.43% 的公司股份在會議上得到了代表。InMed 專注於開發針對高未滿足需求疾病的小分子藥物候選者</p>

<p>Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (&#34; <strong>InMed</strong>&#34; or the &#34; <strong>Company</strong>&#34;), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the &#34; <strong>Meeting</strong>&#34;), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated November 3, 2025, were voted upon by the shareholders. A total of 993,491 common shares of the Company, representing approximately 35.43% of the Company's 2,804,186 issued and outstanding common shares, were represented in person or by proxy at the Meeting.</p>
<div class="lb-trans"><p>温哥華，不列顛哥倫比亞省 --（Newsfile Corp. -2025 年 12 月 17 日）- InMed Pharmaceuticals Inc.（納斯達克：INM）（&#34; <strong>InMed</strong>&#34;或&#34; <strong>公司</strong>&#34;），是一家專注於開發針對高未滿足醫療需求疾病的專有小分子藥物候選者的製藥公司，今天確認，在 2025 年 12 月 17 日舉行的年度股東大會和特別股東會議（&#34; <strong>會議</strong>&#34;）上，股東們對 InMed 在 2025 年 11 月 3 日發佈的會議通知和管理信息通函中提出的事項進行了投票。會議上，共有 993,491 股公司的普通股，約佔公司已發行和流通的 2,804,186 股普通股的 35.43%，以親自或委託代理的方式出席。</p>
</div><p>Results of the vote for the election of the board of directors (the &#34; <strong>Board</strong>&#34;) at the Meeting are set out as follows:</p>
<div class="lb-trans"><p>會議上董事會（&#34; <strong>董事會</strong>&#34;）選舉的投票結果如下：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Director</strong></td>
<td><strong>Votes For</strong></td>
<td><strong>Withheld Votes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number</strong></td>
<td><strong>Percentage</strong></td>
<td><strong>Number</strong></td>
<td><strong>Percentage</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Eric A. Adams</strong></td>
<td>125,352</td>
<td>82.03%</td>
<td>27,469</td>
<td>17.98%</td>
</tr>
<tr>
<td><strong>Andrew Hull</strong></td>
<td>125,315</td>
<td>82.00%</td>
<td>27,506</td>
<td>18.00%</td>
</tr>
<tr>
<td><strong>Nicole Lemerond</strong></td>
<td>125,485</td>
<td>82.11%</td>
<td>27,336</td>
<td>17.89%</td>
</tr>
<tr>
<td><strong>Neil Klompas</strong></td>
<td>125,444</td>
<td>82.09%</td>
<td>27,377</td>
<td>17.91%</td>
</tr>
<tr>
<td><strong>John Bathery</strong></td>
<td>125,227</td>
<td>81.94%</td>
<td>27,594</td>
<td>18.06%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>董事</strong></td>
<td><strong>贊成票</strong></td>
<td><strong>棄權票</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>數量</strong></td>
<td><strong>百分比</strong></td>
<td><strong>數量</strong></td>
<td><strong>百分比</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Eric A. Adams</strong></td>
<td>125,352</td>
<td>82.03%</td>
<td>27,469</td>
<td>17.98%</td>
</tr>
<tr>
<td><strong>Andrew Hull</strong></td>
<td>125,315</td>
<td>82.00%</td>
<td>27,506</td>
<td>18.00%</td>
</tr>
<tr>
<td><strong>Nicole Lemerond</strong></td>
<td>125,485</td>
<td>82.11%</td>
<td>27,336</td>
<td>17.89%</td>
</tr>
<tr>
<td><strong>Neil Klompas</strong></td>
<td>125,444</td>
<td>82.09%</td>
<td>27,377</td>
<td>17.91%</td>
</tr>
<tr>
<td><strong>John Bathery</strong></td>
<td>125,227</td>
<td>81.94%</td>
<td>27,594</td>
<td>18.06%</td>
</tr>
</tbody>
</table>
</div><p>In addition, shareholders voted to approve CBIZ CPAs P.C. as the Company's auditors for the following year.</p>
<div class="lb-trans"><p>此外，股東們投票批准 CBIZ CPAs P.C.作為公司下一年的審計師。</p>
</div><p>Shareholders also voted to approve the potential issuance of 20% or more of the Company's common shares issued and outstanding as of December 13, 2024, pursuant to the Standby Equity Purchase Agreement with YA II PN, Ltd., as amended on June 13, 2025, pursuant to Nasdaq Listing Rules 5635(d) and 5635(b) (the &#34; <strong>SEPA</strong>&#34;).</p>
<div class="lb-trans"><p>股東們還投票批准根據與 YA II PN, Ltd.於 2025 年 6 月 13 日修訂的備用股權購買協議，潛在發行 20% 或更多截至 2024 年 12 月 13 日公司已發行和流通的普通股，符合納斯達克上市規則 5635(d) 和 5635(b)（&#34; <strong>SEPA</strong>&#34;）。</p>
</div><p>InMed filed a report of voting results on SEDAR+ at www.sedarplus.ca on December 17, 2025.</p>
<div class="lb-trans"><p>InMed 於 2025 年 12 月 17 日在 SEDAR+ 上提交了投票結果報告，網址為 www.sedarplus.ca。</p>
</div><p><strong>About InMed:</strong></p>
<div class="lb-trans"><p><strong>關於 InMed：</strong></p>
</div><p>InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.</p>
<div class="lb-trans"><p>InMed Pharmaceuticals 是一家專注於開發針對 CB1/CB2 受體的專有小分子藥物候選者的製藥公司。InMed 的產品線包括針對阿爾茨海默病、眼科和皮膚科適應症的三個獨立項目。有關更多信息，請訪問 www.inmedpharma.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information:</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性信息的警示説明：</strong></p>
</div><p>This news release, and oral statements by the Company and its executive officers and directors, contain &#34;forward-looking information&#34; and &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as &#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;potential&#34;, &#34;possible&#34;, &#34;would&#34; and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information includes, but is not limited to, statements about H.R. 5371, the &#34;Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026&#34; (the &#34; <strong>Act</strong>&#34;), the impact of the Act on BayMedica Inc., any potential modifications to the Act and/or the timing thereof and the alternative options available to BayMedica and the Company, statements about developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, and statements about the potential issuance of common shares pursuant to the SEPA.</p>
<div class="lb-trans"><p>本新聞稿及公司及其高管和董事的口頭聲明包含適用證券法意義上的&#34;前瞻性信息&#34;和&#34;前瞻性聲明&#34;（統稱為&#34;前瞻性信息&#34;）。前瞻性聲明通常通過&#34;預計&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;潛在&#34;、&#34;可能&#34;、&#34;將&#34;及類似表達來識別。這些聲明基於管理層當前的預期，固有地涉及許多已知和未知的風險、不確定性和假設，其中許多超出我們的控制。前瞻性信息基於管理層當前的期望和信念，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與前瞻性聲明中描述的結果有實質性差異。在不限制前述內容的情況下，前瞻性信息包括但不限於關於 H.R. 5371，即&#34;2026 年持續撥款、農業、立法部門、軍事建設和退伍軍人事務及擴展法案&#34;（&#34; <strong>法案</strong>&#34;）的聲明，法案對 BayMedica Inc.的影響，法案的任何潛在修改及/或其時機，以及 BayMedica 和公司的可選方案，關於開發針對高未滿足醫療需求疾病的專有小分子藥物候選者的聲明，以及關於根據 SEPA 潛在發行普通股的聲明。</p>
</div><p>Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any other documents filed or furnished with the Securities and Exchange Commission available on www.sec.gov.</p>
<div class="lb-trans"><p>此外，存在已知和未知的風險因素，可能導致 InMed 的實際結果、表現或成就與前瞻性信息中表達或暗示的任何未來結果、表現或成就有實質性差異。InMed 的年度報告（10-K 表格）及其季度報告（10-Q 表格）、當前報告（8-K 表格）以及向證券交易委員會提交或提供的任何其他文件中披露了 InMed 業務面臨的風險和不確定性。</p>
</div><p>All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.</p>
<div class="lb-trans"><p>本文件中的所有前瞻性信息均受到本警示聲明的完全限制，InMed 不承擔修訂或更新任何此類前瞻性信息的義務，也不承擔公開宣佈任何修訂結果以反映未來結果、事件或發展的義務，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/9540/278446_a7fda5c4c43f1b03_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278446</p>
<div class="lb-trans"><p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/278446</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/278446/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/278446/375"/></p>

InMed 宣佈 2025 年度股東大會及特別會議結果 | INM 股票新聞